A Study to Learn How Well the Study Treatment Asundexian Works and How Safe it is Compared to Apixaban to Prevent Stroke or Systemic Embolism in People With Irregular and Often Rapid Heartbeat (Atrial Fibrillation), and at Risk for Stroke

Clinical trial NCT05643573 · TERMINATED

Trial details

NCT number: NCT05643573
Sponsor: Bayer
Status: TERMINATED
Phase: Phase 3
Study type: INTERVENTIONAL

Prevention of Stroke or Systemic Embolism Atrial Fibrillation

Start date: 2022-12-05
Primary completion: 2024-01-31
Enrollment: 14830

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.